Table 2.

HLA-E and HLA-G expression by tumor cells

HLA-EHLA-G
Patient n°Histologic typepTNMTANTPANTDATANTPANTDA
31ADCT1N0M0nanana+++++++++
32ADCT1N0M0nanana++++++++
33ADCT1N0M0++++±±++++++++
34ADCT1N2M0++--+++++++++
35ADCT1N2M0++--++++++na
36ADCT1N2M0---+++++na
37ADCT2N0M0+++±na+++++++na
38ADCT2N0M0nanana++++++++++
39ADCT2N0M0+--nanana
40ADCT2N1M0nana-+++++
41ADCT2N2M0--±+++++++
42ADCT2N2M0+-±++++++++
43ADCT3N0M0+-+-+++++
44SCCT2N0M0++++---+++++
45SCCT2N0M0+++---+++++
46SCCT2N1M0+++---+++
47SCCT2N1M0----+++++
48SCCT2N2M0nanana++++
49SCCT2N2M0----++++
50SCCT3N0M0----++++
51LCCT2N0M0++---+++na
52LCCT2N1M0++±±-++++

NOTE: HLA-E and HLA-G expression was determined in ADC, SCC, and LCC in tumor area (TA), nontumoral proximal area (NTPA), nontumoral distal area (NTDA). The scores indicate the results of a semiquantitative analysis of positivity. -: no detectable expression, ±: less than 5%; +: 5% to 10%; ++: 10% to 50%; +++: 50% to 100%; ++++: 100% of cells express the ligand. na: data not available.